ERBB2 and breast carcinoma: A key study by Rhodes et al. [59] found that AT1R is overexpressed in 10%–20% of breast cancer cases, particularly in a subset of oestrogen receptor-positive, ERBB2-negative breast cancers, suggesting potential benefits from ARB therapy, especially losartan.